Innate Pharma (IPHYF) Long-Term Investments (2017 - 2025)

Innate Pharma's Long-Term Investments history spans 9 years, with the latest figure at $12.2 million for Q4 2025.

  • For Q4 2025, Long-Term Investments rose 10.78% year-over-year to $12.2 million; the TTM value through Dec 2025 reached $12.2 million, up 10.78%, while the annual FY2025 figure was $12.2 million, 9.37% up from the prior year.
  • Long-Term Investments reached $12.2 million in Q4 2025 per IPHYF's latest filing, up from $11.0 million in the prior quarter.
  • In the past five years, Long-Term Investments ranged from a high of $45.6 million in Q4 2021 to a low of $10.5 million in Q4 2023.
  • Average Long-Term Investments over 5 years is $23.0 million, with a median of $12.2 million recorded in 2025.
  • Peak YoY movement for Long-Term Investments: plummeted 70.58% in 2023, then increased 10.78% in 2025.
  • A 5-year view of Long-Term Investments shows it stood at $45.6 million in 2021, then fell by 21.46% to $35.8 million in 2022, then crashed by 70.58% to $10.5 million in 2023, then grew by 4.23% to $11.0 million in 2024, then grew by 10.78% to $12.2 million in 2025.
  • Per Business Quant, the three most recent readings for IPHYF's Long-Term Investments are $12.2 million (Q4 2025), $11.0 million (Q4 2024), and $10.5 million (Q4 2023).